Analysts Set Novo Nordisk A/S (NYSE:NVO) PT at $112.00

Novo Nordisk A/S (NYSE:NVO) has earned an average recommendation of “Hold” from the eleven research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $112.00.

NVO has been the topic of several research analyst reports. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. BMO Capital Markets restated a “market perform” rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Finally, BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating on the stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $69.05 on Wednesday. The stock has a market cap of $308.31 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The stock has a 50 day moving average of $69.96 and a 200-day moving average of $75.92. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $143.69.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion during the quarter. On average, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. lifted its stake in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after buying an additional 23,223 shares during the last quarter. North Star Investment Management Corp. increased its holdings in shares of Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company’s stock valued at $1,440,000 after purchasing an additional 3,200 shares during the period. Stanley Laman Group Ltd. acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at $390,000. Dover Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at $505,000. Finally, Natural Investments LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $1,345,000. 11.54% of the stock is currently owned by institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.